title: Impact of recombinant platelet-derived growth factor BB on bone regeneration: a study in rabbits.
abstract: The aim of this study was to test whether recombinant human platelet-derived growth factor BB (rhPDGF-BB) enhances bone regeneration in combination with Β-tricalcium phosphate (Β-TCP) granules or deproteinized bovine bone mineral (DBBM) compared to empty defects and Β-TCP granules alone. Four titanium cylinders were placed on the external cortical plates of seven rabbits' calvaria and randomly allocated to one of four groups: (1) empty, (2) Β-TCP, (3) Β-TCP + rhPDGF-BB, and (4) DBBM + rhPDGF-BB. The mean area of bone regeneration was 13.9% ± 8.4% (empty), 24.0% ± 14.8% (Β-TCP), 37.1% ± 8.9% (Β-TCP + rhPDGF-BB), and 64.4% ± 5.4% (DBBM + rhPDGF-BB), with the greatest bone regeneration noted for DBBM + rhPDGF-BB (P < .01). The fraction of bone substitute material varied between 48.3% ± 9.3% (DBBM + rhPDGF-BB), 53.1% ± 10.6% (Β-TCP + rhPDGF-BB), and 58.0% ± 14.8% (Β-TCP). rhPDGF-BB combined with DBBM showed the greatest potential to enhance bone regeneration.
authors.affiliation: Clinic of Fixed and Removable Prosthodontics and Dental Material Science, University of Zurich, Zurich, Switzerland. daniel.thoma@zzm.uzh.ch
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Thoma
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Jung
authors.forename: Patrick
authors.initials: P
authors.lastname: Hänseler
authors.forename: Christoph H F
authors.initials: CH
authors.lastname: Hämmerle
authors.forename: David L
authors.initials: DL
authors.lastname: Cochran
authors.forename: Franz E
authors.initials: FE
authors.lastname: Weber
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000818:Animals; D000077214:Becaplermin; D001857:Bone Matrix / Q000637:transplantation; D001861:Bone Regeneration / Q000187:drug effects*; D018786:Bone Substitutes / Q000627:therapeutic use; D002130:Calcium Phosphates / Q000627:therapeutic use; D002417:Cattle; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008903:Minerals / Q000627:therapeutic use; D010012:Osteogenesis / Q000187:drug effects; D020574:Proto-Oncogene Proteins c-sis / Q000627:therapeutic use*; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins; D012886:Skull / Q000473:pathology / Q000601:surgery
chemical_list: D043925:Angiogenesis Inducing Agents; C077540:Bio-Oss; D018786:Bone Substitutes; D002130:Calcium Phosphates; D008903:Minerals; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; C485817:beta-tricalcium phosphate; D000077214:Becaplermin